Theseus Pharmaceuticals Inc (NASDAQ: THRX) shares nose-dived after the company announced discontinuing enrollment in the ongoing phase 1/2 study and terminating the development of THE-630 in patients with gastrointestinal stromal tumors (GIST) after reporting